BMEA ownership update: Cormorant group reports 5.15% (3.57M) stake

Rhea-AI Filing Summary

This amendment reports that a Cormorant investment group and director Bihua Chen together hold a meaningful minority stake in Biomea Fusion, Inc. The filing discloses group-wide shared voting and dispositive power over 3,570,872 shares, equal to 5.15% of common stock, and that Ms. Chen separately holds or controls an additional 110,792 shares and options exercisable within 60 days, bringing her aggregate economic interest to 3,681,664 shares or 5.31% of the company.

The percentage calculations use a post-offering share count of 69,322,377 common shares as stated in the filing materials. The filing also notes there were no transactions in the issuer's securities by the reporting persons during the sixty-day period before this statement, and it updates identity, citizenship, and source-of-funds information for the reporting entities.

Positive

• Aggregate stake of 5.31% signals a material, disclosed position by an investor and a director
• Clear breakdown of shared vs. sole voting/dispositive power improves transparency for shareholders
• No transactions in the prior 60 days indicates holdings were stable at the time of this filing

Negative

• None.

Insights

Investor Relations Analyst

Cormorant and director holdings cross the 5% threshold, creating a visible shareholder block.

The group reports shared control of 3,570,872 shares (5.15%) while the director's aggregate holdings, including options exercisable within 60 days, total 3,681,664 shares (5.31%), calculated on a stated outstanding base of 69,322,377 shares.

This level of disclosed ownership is large enough to matter for governance and votes on routine corporate actions; the filing also confirms no transactions in the prior sixty days. Watch for any subsequent amendments or open-market activity that change these percentages near corporate votes or financing actions.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 3)

Biomea Fusion, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

09077A106

(CUSIP Number)

Neb Obradovic
Cormorant Asset Management, L.P., 200 Clarendon Street, 52nd Floor
Boston, MA, 02116
857-702-0386

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

10/08/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 09077A106

1

Name of reporting person

Cormorant Global Healthcare Master Fund, LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,795,928.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,795,928.00

11

Aggregate amount beneficially owned by each reporting person

1,795,928.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

2.59 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP No. 09077A106

1

Name of reporting person

Cormorant Global Healthcare GP, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,795,928.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,795,928.00

11

Aggregate amount beneficially owned by each reporting person

1,795,928.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

2.59 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP No. 09077A106

1

Name of reporting person

Cormorant Private Healthcare Fund III LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,717,232.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,717,232.00

11

Aggregate amount beneficially owned by each reporting person

1,717,232.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

2.48 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP No. 09077A106

1

Name of reporting person

Cormorant Private Healthcare GP III, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,717,232.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,717,232.00

11

Aggregate amount beneficially owned by each reporting person

1,717,232.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

2.48 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP No. 09077A106

1

Name of reporting person

Cormorant Asset Management, LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 3,570,872.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 3,570,872.00

11

Aggregate amount beneficially owned by each reporting person

3,570,872.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

5.15 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP No. 09077A106

1

Name of reporting person

Chen Bihua

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 110,792.00
8	Shared Voting Power 3,570,872.00
9	Sole Dispositive Power 110,792.00
10	Shared Dispositive Power 3,570,872.00

11

Aggregate amount beneficially owned by each reporting person

3,681,664.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

5.31 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock
(b)	Name of Issuer: Biomea Fusion, Inc.
(c)	Address of Issuer's Principal Executive Offices: 1599 INDUSTRIAL ROAD, SAN CARLOS, CALIFORNIA , 94070.
Item 1 Comment: This Amendment No. 3 to Schedule 13D (this "Amendment") relates to Common Stock of Biomea Fusion, Inc., a Delaware corporation (the "Issuer" or the "Company"). The address of the principal executive offices of the Issuer is 1599 Industrial Road, San Carlos, CA 94070. This Amendment is being filed by the Reporting Persons to amend the Schedule 13D that was filed on April 30, 2021, as amended by Amendment No. 1 filed on April 3, 2023, and Amendment No. 2 filed on July 22, 2025 (as so amended, the "Schedule 13D"). Unless otherwise indicated, all capitalized terms used herein but not defined herein shall have the same meaning as in the Schedule 13D.
Item 2.	Identity and Background
(a)	Cormorant Global Healthcare Master Fund, LP Cormorant Global Healthcare GP, LLC Cormorant Private Healthcare Fund III, LP Cormorant Private Healthcare GP III, LLC Cormorant Asset Management, LP Bihua Chen
(b)	200 Clarendon Street, 52nd Floor Boston, MA 02116
(f)	Cormorant Global Healthcare Master Fund, LP - Cayman Islands Cormorant Global Healthcare GP, LLC - Delaware Cormorant Private Healthcare Fund III, LP - Delaware Cormorant Private Healthcare GP III, LLC - Delaware Cormorant Asset Management, LP - Delaware Bihua Chen - United States
Item 5.	Interest in Securities of the Issuer
(a)	See Items 7-13 of the cover page and Item 2.
(b)	See Items 7-13 of the cover page and Item 2. The percentages reported herein with respect to the Reporting Persons' holdings are calculated based upon (i) a statement in a Prospectus filed by the Issuer on October 7, 2025 that there would be 69,322,377 shares of Common Stock outstanding following the closing of a public offering described therein, and (ii) a statement in a Current Report on Form 8-K filed by the Issuer on October 7, 2025 reporting that the public offering was expected to close on October 8, 2025. The shares reported for Bihua Chen reflect shares of Common Stock that she has the right to receive within 60 days upon the exercise of stock options granted to her in her capacity as a director of the Issuer.
(c)	The Reporting Persons did not engage in any transactions in securities of the Issuer during the sixty day period prior to the filing of this Schedule 13D.
(d)	Not applicable.
(e)	Not applicable.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Cormorant Global Healthcare Master Fund, LP

Signature:	/s/ CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP By: Cormorant Global Healthcare GP, LLC, its General Partner
Name/Title:	By: Bihua Chen, Managing Member
Date:	10/10/2025

Cormorant Global Healthcare GP, LLC

Signature:	/s/ Bihua Chen
Name/Title:	By: Bihua Chen, Managing Member
Date:	10/10/2025

Cormorant Private Healthcare Fund III LP

Signature:	/s/ CORMORANT PRIVATE HEALTHCARE FUND III, LP By: Cormorant Private Healthcare GP III, LLC, its General Partner
Name/Title:	By: Bihua Chen, Managing Member
Date:	10/10/2025

Cormorant Private Healthcare GP III, LLC

Signature:	/s/ Bihua Chen
Name/Title:	By: Bihua Chen, Managing Member
Date:	10/10/2025

Cormorant Asset Management, LP

Signature:	/s/ CORMORANT ASSET MANAGEMENT, LP By: Cormorant Asset Management GP, LLC, its General Partner
Name/Title:	By: Bihua Chen, Managing Member
Date:	10/10/2025

Chen Bihua

Signature:	/s/ Bihua Chen
Name/Title:	Bihua Chen
Date:	10/10/2025

FAQ

What stake does Cormorant hold in Biomea Fusion (BMEA)?

Cormorant entities report shared voting and dispositive power over 3,570,872 shares, equal to 5.15% of outstanding common stock.

What is Bihua Chen's total reported ownership in BMEA?

Bihua Chen's aggregate interest is 3,681,664 shares, representing 5.31%, including shares she may receive upon option exercise within 60 days.

What share count was used to calculate the percentages?

Percentages are calculated using a post-offering share count of 69,322,377 common shares as stated in the filing materials.

Did the reporting persons trade BMEA shares in the last 60 days?

No. The filing states the reporting persons did not engage in any transactions during the sixty-day period prior to this statement.

Does the filing change who controls the reported shares?

The filing clarifies shared voting and dispositive power across the Cormorant entities and confirms Ms. Chen's separate sole voting/dispositive power over 110,792 shares.